Description
Ventilator-associated pneumonia (VAP) is an important
cause of morbidity and mortality. The diagnosis of VAP is
not standardised which complicates data analysis. There have
been many trials looking at a variety of interventions which
aim to reduce VAP rates. There is good evidence to support
several equipment related interventions and clear guidelines
have been developed for clinical practice. Recently, new
tracheal tubes which allow secretions resting above the cuff to
be suctioned before they are aspirated have yielded promising
results. In other areas, particularly those involving
pharmacological interventions, the evidence has been
conflicting and contradictory. Larger trials are needed to reassess
the efficacy of many of these interventions and their
effect on VAP rates and length of stay and mortality.
